Celldex Therapeutics, Inc. (CLDX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase.
Is Celldex Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Celldex Therapeutics, Inc. (CLDX) trades at $29.04 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Celldex Therapeutics, Inc.
Market cap $2B · 52 weeks $23 – $45 (35 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS -$1.02 · Closing price, Nov 2 · accounts published Aug 6.
- Valuation: P/Sales 627× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Market cap / Cash 3.7×, fails.
- Cash Runway 29 months, passes.
- Total Debt 0.0×, passes.
- R&D / Market cap 12.7 %, passes.
- Annual cash burn $3.17, info.
Against its peers (reference peers) — Celldex Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -45.1 %; $2.3B. Nurix Therapeutics, Inc. (P/E 11.1×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B), Harmony Biosciences Holdings, Inc. (P/E 12.3×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B), Aurinia Pharmaceuticals Inc. (P/E 7.0×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.1B).
Profitability
| Return on Equity | -52.36% |
| Return on Invested Capital | -45.10% |
| Return on Assets | -38.42% |
| Gross Margin | -56,850.89% |
| Operating Margin | -290,948.21% |
| Net Margin | -268,385.71% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 11.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 14.43 |
Price Performance
| 1 month | -8.25% |
| 3 months | -29.27% |
| Year-to-date | +6.92% |
| 1 year | +17.33% |
| 3 years | +11.78% |
| 5 years | -37.59% |
| 10 years | -37.35% |
Related companies: IMNM · NRIX · XNCR · RCUS
Explore sector: Healthcare · Biotechnology
More sections of CLDX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks